EEWOWW is an online personal knowledge management tool. Click to find out more!
 
Updated in 2018/8/18 上午 05:34:05      Viewed: 87 times      (Document)

ATLAS

ABSTRACT

1. Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. The New England journal of medicine. 2008;359(18):1932-40. doi: 10.1056/NEJMra0707500. PubMed PMID: 18971494.

2. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. Jama. 2015;313(4):398-408. doi: 10.1001/jama.2014.17103. PubMed PMID: 25626036.

3. Mikamo H, Tateda K, Yanagihara K, Kusachi S, Takesue Y, Miki T, et al. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2018. doi: 10.1016/j.jiac.2018.05.010. PubMed PMID: 29934056.

4. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. The Journal of infection. 2009;58(6):403-10. doi: 10.1016/j.jinf.2009.03.010. PubMed PMID: 19394704.

5. Bauer MP, Kuijper EJ, van Dissel JT, European Society of Clinical M, Infectious D. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2009;15(12):1067-79. doi: 10.1111/j.1469-0691.2009.03099.x. PubMed PMID: 19929973.

6. Feher C, Munez Rubio E, Merino Amador P, Delgado-Iribarren Garcia-Campero A, Salavert M, Merino E, et al. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2017;36(2):295-303. doi: 10.1007/s10096-016-2802-x. PubMed PMID: 27718071.

7. Soriano MM, Danziger LH, Gerding DN, Johnson S. Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies. Open forum infectious diseases. 2014;1(2):ofu069. doi: 10.1093/ofid/ofu069. PubMed PMID: 25734139; PubMed Central PMCID: PMC4281782.

8. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012;55 Suppl 2:S154-61. doi: 10.1093/cid/cis462. PubMed PMID: 22752865; PubMed Central PMCID: PMC3388030.

9. Johnson S, Gerding DN. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;56(2):309-10. doi: 10.1093/cid/cis833. PubMed PMID: 23024296.

10. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. The New England journal of medicine. 2017;376(4):305-17. doi: 10.1056/NEJMoa1602615. PubMed PMID: 28121498.

11. Wilcox M, Dorr MB, Pedley A. Bezlotoxumab and Recurrent Clostridium difficile Infection. The New England journal of medicine. 2017;376(16):1594-6. doi: 10.1056/NEJMc1702531. PubMed PMID: 28423298.

12. Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, et al. Bezlotoxumab for prevention of recurrent C. difficile infection in patients at increased risk for recurrence. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018. doi: 10.1093/cid/ciy171. PubMed PMID: 29538686.

13. Lee Y, Lim WI, Bloom CI, Moore S, Chung E, Marzella N. Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection. P & T : a peer-reviewed journal for formulary management. 2017;42(12):735-8. PubMed PMID: 29234211; PubMed Central PMCID: PMC5720485 this article.

14. Prabhu VS, Dubberke ER, Dorr MB, Elbasha E, Cossrow N, Jiang Y, et al. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;66(3):355-62. doi: 10.1093/cid/cix809. PubMed PMID: 29106516.

15. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;57(4):555-61. doi: 10.1093/cid/cit346. PubMed PMID: 23704121; PubMed Central PMCID: PMC3719891.

16. Lam SW, Neuner EA, Fraser TG, Delgado D, Chalfin DB. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting. Infection control and hospital epidemiology. 2018:1-7. doi: 10.1017/ice.2018.139. PubMed PMID: 29961435.

17. Chahine EB, Cho JC, Worley MV. Bezlotoxumab for the Prevention of Clostridium difficile Recurrence. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2018;33(2):89-97. doi: 10.4140/TCP.n.2018.89. PubMed PMID: 29409575.

18. Arora V, Kachroo S, Ghantoji SS, Dupont HL, Garey KW. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. The Journal of hospital infection. 2011;79(1):23-6. doi: 10.1016/j.jhin.2011.04.027. PubMed PMID: 21700363.

19. Zilberberg MD, Shorr AF, Wang L, Baser O, Yu H. Development and Validation of a Risk Score for Clostridium difficile Infection in Medicare Beneficiaries: A Population-Based Cohort Study. Journal of the American Geriatrics Society. 2016;64(8):1690-5. doi: 10.1111/jgs.14236. PubMed PMID: 27295521.

20. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. The New England journal of medicine. 2011;364(5):422-31. doi: 10.1056/NEJMoa0910812. PubMed PMID: 21288078.

21. Hernandez-Garcia R, Garza-Gonzalez E, Miller M, Arteaga-Muller G, Galvan-de los Santos AM, Camacho-Ortiz A. Application of the ATLAS score for evaluating the severity of Clostridium difficile infection in teaching hospitals in Mexico. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2015;19(4):399-402. doi: 10.1016/j.bjid.2015.05.005. PubMed PMID: 26117213.

22. Miller MA, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC infectious diseases. 2013;13:148. doi: 10.1186/1471-2334-13-148. PubMed PMID: 23530807; PubMed Central PMCID: PMC3618004.

23. Jacobson SM, Slain D. Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2015;72(21):1871-5. doi: 10.2146/ajhp150076. PubMed PMID: 26490821.

24. Mulherin DW, Hutchison AM, Thomas GJ, Hansen RA, Childress DT. Concordance of the SHEA-IDSA severity classification for Clostridium difficile infection and the ATLAS bedside scoring system in hospitalized adult patients. Infection. 2014;42(6):999-1005. doi: 10.1007/s15010-014-0671-8. PubMed PMID: 25129565.

25. Laza R, Jurac R, Crisan A, Lazureanu V, Licker M, Popovici ED, et al. Clostridium difficile in western Romania: unfavourable outcome predictors in a hospital for infectious diseases. BMC infectious diseases. 2015;15:141. doi: 10.1186/s12879-015-0895-y. PubMed PMID: 25881288; PubMed Central PMCID: PMC4372176.

26. Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015;21(2):164-70. doi: 10.1016/j.cmi.2014.08.017. PubMed PMID: 25658560.

27. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. The New England journal of medicine. 2015;372(9):825-34. Epub 2015/02/26. doi: 10.1056/NEJMoa1408913. PubMed PMID: 25714160.

28. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377(9759):63-73. Epub 2010/11/19. doi: 10.1016/S0140-6736(10)61266-4. PubMed PMID: 21084111.

29. Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;53(12):1173-8. Epub 2011/10/07. doi: 10.1093/cid/cir668. PubMed PMID: 21976459.

30. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012;18 Suppl 6:21-7. Epub 2012/11/21. doi: 10.1111/1469-0691.12046. PubMed PMID: 23121551.

31. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007;45(3):302-7. Epub 2007/06/30. doi: 10.1086/519265. PubMed PMID: 17599306.

32. Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A, Nault V, Valiquette L. Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;62(5):574-80. Epub 2015/11/20. doi: 10.1093/cid/civ958. PubMed PMID: 26582748.

33. Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PloS one. 2014;9(6):e98400. Epub 2014/06/05. doi: 10.1371/journal.pone.0098400. PubMed PMID: 24897375; PubMed Central PMCID: PMCPMC4045753.

34. Inns T, Gorton R, Berrington A, Sails A, Lamagni T, Collins J, et al. Effect of ribotype on all-cause mortality following Clostridium difficile infection. The Journal of hospital infection. 2013;84(3):235-41. Epub 2013/06/14. doi: 10.1016/j.jhin.2013.04.008. PubMed PMID: 23759667.

35. See I, Mu Y, Cohen J, Beldavs ZG, Winston LG, Dumyati G, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;58(10):1394-400. Epub 2014/03/08. doi: 10.1093/cid/ciu125. PubMed PMID: 24604900; PubMed Central PMCID: PMCPMC4697926.

36. Kim S, McClave SA, Martindale RG, Miller KR, Hurt RT. Hypoalbuminemia and Clinical Outcomes: What is the Mechanism behind the Relationship? The American surgeon. 2017;83(11):1220-7. PubMed PMID: 29183523.

37. Palau-Davila L, Garza-Gonzalez E, Gutierrez-Delgado EM, Camacho-Ortiz A. Predictors of severe outcomes in patients with Clostridium difficile infection from a Hispanic population. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. 2017;36(1):38-42. doi: 10.1007/s12664-016-0722-4. PubMed PMID: 27987135.

38. Rotramel A, Poritz LS, Messaris E, Berg A, Stewart DB. PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics. J Gastrointest Surg. 2012;16(12):2267-73. Epub 2012/09/26. doi: 10.1007/s11605-012-2037-9. PubMed PMID: 23007285.